Market research
POLX.LSE Polarean Imaging plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 966K
- P/E ratio
- Not available
- Analyst target
- 4.0284
- Dividend yield
- Not available
- Beta
- 0.28
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- GB00BF3DT583
- Market cap
- 966K
- P/E ratio
- Not available
- Analyst target
- 4.0284
- Dividend yield
- Not available
- Beta
- 0.28
About
About Polarean Imaging plc
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag. Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the POLX.LSE discussion.
5 years, 4 months ago
Polarean Imaging plc is currently in a long term uptrend where the price is trading 25.1% above its 200 day moving average.
From a valuation standpoint, the stock is 88.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 50.5.
Based on the above factors, Polarean Imaging plc gets an overall score of 2/5.